# LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

> **NCT03053596** · — · COMPLETED · sponsor: **Terumo Europe N.V.** · enrollment: 102 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** DEB-TACE using anthracyclin loaded LifePearl™

## Key facts

- **NCT ID:** NCT03053596
- **Lead sponsor:** Terumo Europe N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-04-01
- **Final completion:** 2019-10-08
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053596, "LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03053596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*